What is Leede Financial’s Estimate for CRDL FY2027 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Equities researchers at Leede Financial dropped their FY2027 EPS estimates for shares of Cardiol Therapeutics in a note issued to investors on Tuesday, November 19th. Leede Financial analyst D. Loe now expects that the company will post earnings of $0.16 per share for the year, down from their previous forecast of $0.18. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.36) per share. Leede Financial also issued estimates for Cardiol Therapeutics’ FY2028 earnings at $0.74 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research note on Wednesday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Cardiol Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $8.75.

Cardiol Therapeutics Trading Down 5.5 %

Cardiol Therapeutics stock opened at $1.56 on Wednesday. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $1.98 and a two-hundred day moving average price of $2.09. The firm has a market capitalization of $127.30 million, a price-to-earnings ratio of -4.23 and a beta of 0.91. Cardiol Therapeutics has a 52-week low of $0.79 and a 52-week high of $3.12.

Hedge Funds Weigh In On Cardiol Therapeutics

Several institutional investors have recently added to or reduced their stakes in CRDL. Jane Street Group LLC acquired a new stake in shares of Cardiol Therapeutics during the 3rd quarter worth approximately $29,000. Townsquare Capital LLC acquired a new stake in shares of Cardiol Therapeutics during the 3rd quarter worth approximately $27,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Cardiol Therapeutics during the 3rd quarter worth approximately $27,000. Foundations Investment Advisors LLC grew its position in shares of Cardiol Therapeutics by 237.4% during the 3rd quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company’s stock worth $321,000 after buying an additional 113,950 shares during the period. Finally, Lion Street Advisors LLC grew its position in shares of Cardiol Therapeutics by 7.9% during the 3rd quarter. Lion Street Advisors LLC now owns 273,281 shares of the company’s stock worth $544,000 after buying an additional 20,000 shares during the period. 12.49% of the stock is owned by institutional investors.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.